Ultragenyx Pharmaceutical Valuation
Is RARE * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RARE * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RARE * (MX$751.98) is trading below our estimate of fair value (MX$3519.46)
Significantly Below Fair Value: RARE * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RARE *?
Other financial metrics that can be useful for relative valuation.
What is RARE *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$4.16b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7.9x |
Enterprise Value/EBITDA | -6.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RARE *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.6x | ||
LAB B Genomma Lab Internacional. de | 1x | 8.2% | Mex$16.3b |
ALKS Alkermes | 2.4x | -2.5% | US$4.1b |
002007 Hualan Biological Engineering | 5.6x | 15.3% | CN¥29.3b |
301301 Yili Chuanning BiotechnologyLtd | 5.6x | 11.1% | CN¥28.3b |
RARE * Ultragenyx Pharmaceutical | 9.6x | 30.6% | Mex$4.2b |
Price-To-Sales vs Peers: RARE * is good value based on its Price-To-Sales Ratio (9.6x) compared to the peer average (20x).
Price to Earnings Ratio vs Industry
How does RARE *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: RARE * is good value based on its Price-To-Sales Ratio (9.6x) compared to the Global Biotechs industry average (10.9x).
Price to Sales Ratio vs Fair Ratio
What is RARE *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 9.6x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate RARE *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.